12月15日,以色列Pharma Two B公司宣布,P2B001在早期帕金森病(PD)患者中进行的一项Ⅲ期临床试验达到其主要和关键次要终点。P2B001是普拉克索(0.6 mg)和雷沙吉兰(0.75 mg)缓释制剂的一种新型固定剂量组合,两种成分的剂量均低于其各自上市产品剂量。试验结果表明,P2B001与上市的普拉克索缓释疗法相比,在疗效相似的情况...
广州爱纯医药科技有限公司020-39119399 18927568969isunpharm@qq.com中国467455 TargetMol中国(陶术生物)021-021-33632979 15002134094marketing@targetmol.com中国778358 上海喀露蓝科技有限公司18149758185 18149758185sales-cpd@caerulumpharma.com中国346658 Sigma-Aldrich西格玛奥德里奇(上海)贸易有限公司021-61415566 800-8193336...
上海毕得医药科技股份有限公司400-1647117 13681763483product02@bidepharm.com中国6207258 武汉绿景丰华生物科技有限公司19972070065201746457@qq.com中国642858 武汉英诺医药科技有限公司+86-027-59232304 153870631012881924050@qq.com中国1000058 湖北威德利化学试剂有限公司13339985473C13339985473@163.com中国463358 ...
DrugsStatusIndicationsR&D Company Ibrutinib launched CLL, MCL, WM, ABC-DLBCL Pharmacyclics/Johnson Acalabrutinib launched MCL AstraZeneca/Acerta Pharm BV Zanubrutinib launched CLL, MCL, FL, WM, SLL BeiGene Orelabrutinib NDA MCL, CLL, SLL, WM Avila/Celegene Tirabrutinib launched Recurrent...
国外投融资方面,医药领域,生物制药公司“CinCor Pharma”以约18亿美元被并购;医疗服务领域,肾脏护理公司“Monogram Health”获得3.75亿美元战略投资。 自2023年1月9日起至2023年1月15日,钛媒体TMTBASE全球一级市场数据库总计收录国内、国外医疗健康赛道投融资事件共81起,其中国内融资37起,国外融资44起。
例如,Dr.Reddy’s Laboratories Ltd.被认为是与Dr.Reddy’sLaboratories Inc.是同一申请人,Endo Pharmaceuticals Inc.被认为与Endo Pharms Inc.是相同申请人。无论申请人是否为法律上不同的实体,同一制药公司的分公司或关联方的申请人也被归类为单一申请人。因此,...
J Pharm Pharmacol 39: 664–666. Aston-Jones G, Rajkowski J, Kubiak P (1997). Conditioned responses of monkey locus coeruleus neurons anticipate acquisition of discriminative behavior in a vigilance task. Neuroscience 80: 697–715. Banna KM, Back SE, Do P, See RE (2010). Yohimbine stress ...
Abbas, PharmD; Ricardo Rocha, MD; Gary F. Mitchell, MD; for the EVALUATE-HF Investigators JAMA Viewpoint Redefining Heart Failure With a Reduced Ejection Fraction Javed Butler, MD, MPH, MBA; Stefan D. Anker, MD; Milton Packer, MD JAMA Review Heart Failure With Reduced Ejection Fraction: ...
Professional medical writing support was provided by Beth Lesher, PharmD, BCPS, and Catherine Mirvis of Pharmerit International LP, and was funded by Millennium Pharmaceuticals, Inc., Cambridge, MA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited. SP acknowledges NHS funding to ...
Pharm 13:1395. https://doi.org/10.3390/pharmaceutics13091395 Article CAS Google Scholar Adler CH, Singer C, O’Brien C et al (1998) Randomized, placebo-controlled study of tolcapone in patients with fluctuating Parkinson disease treated with levodopa-carbidopa. Tolcapone Fluctuator Study Group ...